candesartan has been researched along with Hepatorenal Syndrome in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan is an angiotensin II (Ang II) receptor antagonist with promising diverse health benefits." | 5.91 | Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. ( Ahmed, MA; Ali, FEM; Gad-Elrab, WM; Hassanein, EHM; Kamel, EO; Mohammedsaleh, ZM, 2023) |
| "Candesartan is an angiotensin II (Ang II) receptor antagonist with promising diverse health benefits." | 1.91 | Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. ( Ahmed, MA; Ali, FEM; Gad-Elrab, WM; Hassanein, EHM; Kamel, EO; Mohammedsaleh, ZM, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamel, EO | 1 |
| Gad-Elrab, WM | 1 |
| Ahmed, MA | 1 |
| Mohammedsaleh, ZM | 1 |
| Hassanein, EHM | 1 |
| Ali, FEM | 1 |
1 other study available for candesartan and Hepatorenal Syndrome
| Article | Year |
|---|---|
Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals.
Topics: Angiotensin II; bcl-2-Associated X Protein; Cadmium; Hepatorenal Syndrome; Humans; NF-E2-Related Fac | 2023 |